

## OZANIMOD

2016

TOUCHSTONE

RCT phase 2/ Ozanimod 0.5mg, 1 mg daily vs placebo/ Mod-Severe UC/ Induction

Conclusion:

**Ozanimod at a daily dose of 1 mg resulted in a slightly higher rate of clinical remission of UC than placebo.**

2020

STEPSTONE

RCT phase 2 / Ozanimod 1mg/day orally/ Mod-Severe CD/ Induction

Conclusion:

**Endoscopic, histological, and clinical improvements were seen within 12 weeks of initiating ozanimod therapy in patients with moderately to severely active CD.**

2021

TRUE NORTH

RCT phase 3 / Ozanimod 1mg/day orally/ Mod-Severe UC/ Induction & Maintenance

Conclusion:

**Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis**